Nyxoah enrolls first patient in U.S. post-approval Genio study

Go back to Nyxoah enrolls first patient in U.S. post-approval Genio study
(NASDAQ: NYXH) Delayed: 0.83 -0.06 (6.74%)
Previous Close $0.89    52 Week High $ 
Open $0.85    52 Week Low $ 
Day High $0.86    P/E N/A 
Day Low $0.81    EPS $ 
Volume 418,452